Learn more about Cerezyme
and talk to your doctor to see if
Cerezyme is right for you.
Cerezyme® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with
Type 1 Gaucher disease that results in one or more of the following conditions:Cerezyme (Imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:
Allergic Reactions, Including Anaphylaxis:
Patients treated with enzyme replacement therapies have experienced allergic reactions, including severe or life-threatening reactions (known as anaphylaxis).
Anaphylaxis has occurred during the early course and after repeated treatment with enzyme replacement therapy.
Your healthcare professional should initiate Cerezyme in a healthcare setting with appropriate medical monitoring and support measures. If a severe allergic or anaphylactic reaction occurs, your healthcare professional will immediately stop the infusion and provide appropriate medical treatment. Seek immediate medical care should symptoms occur.
Allergic Reactions (Including Anaphylaxis) and Infusion-Associated Reactions (IARs):
Signs of an allergic reaction reported during or shortly after an infusion included itching, flushing, hives, swelling under the skin, chest discomfort, shortness of breath, coughing, a bluish discoloration of the skin due to diminished oxygen, rapid heart rate, and low blood pressure.
Signs of an infusion reaction included, rash, chills, fatigue, infusion-site burning, infusion-site discomfort, or infusion-site swelling, and fever.
Tell your healthcare professional right away if you experience any reactions. Your healthcare professional may slow or stop the infusion or may lower the next dose. Your healthcare professional may decide to give you antihistamine, anti-fever, and/or steroid medications before your infusions and monitor you for new signs and symptoms of a reaction.
Immune Responses:
Approximately 15% of patients treated and tested to date have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction. Your healthcare professional may periodically test for the presence of antibodies.
Please see Full Prescribing Information, including BOXED WARNING, for CEREZYME.